Session » Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster II

9:00AM-11:00AM

Abstract Number: 2228

A Validated Script Concordance Test Demonstrates Interdisciplinary Differences in Clinical Decision-Making When Using Allopurinol to Treat Gout in Chronic Kidney Disease

9:00AM-11:00AM

Abstract Number: 2233

Activation and Deficiency of Circulating Mucosal-Associated Invariant T Cells in Patients with Gouty Arthritis

9:00AM-11:00AM

Abstract Number: 2231

An Ancestral-Specific Interaction of TRIM46 with a Past-History of Smoking May Influence Gout Risk

9:00AM-11:00AM

Abstract Number: 2251

Calcific Tendonitis of the Rotator Cuff: Do We Need Steroid Injection after Ultrasound Guided Percutaneous Lavage? Results of a 12-Months Double-Blind Randomized Controlled Study

9:00AM-11:00AM

Abstract Number: 2229

Can We Predict Inadequate Response to Allopurinol Dose Escalation? Analysis of a Randomized Controlled Trial

9:00AM-11:00AM

Abstract Number: 2253

Cardiovascular Disease, Other Purported Risk Factors, and Allopurinol-Associated Severe Cutaneous Adverse Reactions: A General Population-Based Cohort Study

9:00AM-11:00AM

Abstract Number: 2242

Cardiovascular Outcomes of Treatment with Febuxostat and Allopurinol in Gout Patients with Kidney Disease

9:00AM-11:00AM

Abstract Number: 2217

Clinical Characteristics of Early Onset Gout in Outpatient Setting

9:00AM-11:00AM

Abstract Number: 2244

Comparison of an Interactive Voice Response (IVR) to Smart Phone App to Determine Patient Preference for Reporting Gout Flares

9:00AM-11:00AM

Abstract Number: 2222

Construct Validity of Provisional Remission Criteria for Gout: A Dual Energy CT Study

9:00AM-11:00AM

Abstract Number: 2236

Contemporary Comorbidity Burden of Gout and Hyperuricemia in the US during the Past Decade (National Health And Nutrition Examination Survey [NHANES] 2007-2016)

9:00AM-11:00AM

Abstract Number: 2225

Exploring the Relationship between Gout and Diffuse Idiopathic Skeletal Hyperostosis (DISH): An Epidemiologic and Genetic Study

9:00AM-11:00AM

Abstract Number: 2248

Genetic Variants Identify Interleukin 37 As an Important Anti-Inflammatory Cytokine in Gout in Humans

9:00AM-11:00AM

Abstract Number: 2226

Gout and the Risk of Incident Dementia in the Elderly: A Medicare Claims Study

9:00AM-11:00AM

Abstract Number: 2220

Gout, Flares and Allopurinol Use: A Population Based Study

9:00AM-11:00AM

Abstract Number: 2240

Hip Involvement in Patients with Gout: Results of an Ultrasound Study

9:00AM-11:00AM

Abstract Number: 2255

Increased Cost Burden in an Early Diagnosed Cohort of Uncontrolled Versus Controlled Gout: Analysis of a Large US Payer Database

9:00AM-11:00AM

Abstract Number: 2246

Insulin: Genetic and Physiological Influences on Human Uric Acid Homeostasis

9:00AM-11:00AM

Abstract Number: 2224

Interactions between Serum Urate-Associated Genetic Variants and Sex on Gout Risk in a European Population

9:00AM-11:00AM

Abstract Number: 2234

Liver Safety of Febuxostat Compared with Allopurinol in Gout Patients with Fatty Liver Disease

9:00AM-11:00AM

Abstract Number: 2245

Lubricin/Proteoglycan 4 (PRG4) Inhibits NLRP3 Inflammasome Assembly in Monosodium Urate (MSU)-Crystal Induced Arthritis.

9:00AM-11:00AM

Abstract Number: 2250

Mitigation of Inflammation Induced By Monosodium Urate Crystals in Mice By Treatment with Svp-Rapamycin

9:00AM-11:00AM

Abstract Number: 2235

Monosodium Urate Deposition Distribution in the Knees, Hands, and Feet of Treated Gout Patients: A Dual-Energy CT Study

9:00AM-11:00AM

Abstract Number: 2238

Non-Coding Urate-Associated Variants Function in a Conserved Lincrna Regulatory Domain That Alters MAF transcription

9:00AM-11:00AM

Abstract Number: 2249

Not Just a Swollen Big Toe: Increasing All-Cause Hospitalizations in Patients with Gout in the United States: 1993–2014

9:00AM-11:00AM

Abstract Number: 2247

Predictors of End-Stage Renal Disease (ESRD) in Gout Patients and General Population (GP) Controls – a Role for Interstitial Nephritis, Urate Nephropathy?

9:00AM-11:00AM

Abstract Number: 2232

Prevalence of Gout in the Surviving U.S. Solid Organ Transplant Population

9:00AM-11:00AM

Abstract Number: 2237

Prevalence of Urate-Lowering Therapy Use and Target Urate Level Achievement Among Gout Patients in the United States (National Health And Nutrition Examination Survey [NHANES] 2007-2014)

9:00AM-11:00AM

Abstract Number: 2223

Proton Pump Inhibitors and Risk of Calcium Pyrophosphate Deposition (CPPD) in a Population-Based Study

9:00AM-11:00AM

Abstract Number: 2219

Safety, Pharmacokinetics and Pharmacodynamics of NC-2500, a Novel Xanthine Oxidoreductase Inhibitor, in Healthy Volunteers

9:00AM-11:00AM

Abstract Number: 2252

Serum Urate Ant Its Clearance in Patients with Chronic Kidney Disease Under Peritoneal Dialysis

9:00AM-11:00AM

Abstract Number: 2230

Serum Urate Levels in People with Gout on Dialysis – Are We Achieving Treatment Targets?

9:00AM-11:00AM

Abstract Number: 2243

Sex Difference of the Association between Serum Urate and Blood Pressure in Young Adults

9:00AM-11:00AM

Abstract Number: 2221

Systematic Genetic Analysis of Early-Onset Gout: ABCG2 141K Is the Strongest Predictor

9:00AM-11:00AM

Abstract Number: 2239

Tenocytes Extracted from Rotator Cuff Tendons Are Able to Induce Mineral Deposition in Vitro and Express Genes Related to a Chondrocyte Differentiation

9:00AM-11:00AM

Abstract Number: 2254

Update of SEL-212 Phase 2 Clinical Data in Symptomatic Gout Patients: Svp-Rapamycin Combined with Pegadricase Mitigates Immunogenicity and Enables Sustained Reduction of Serum Uric Acid Levels, Low Rate of Gout Flares and Monthly Dosing

9:00AM-11:00AM

Abstract Number: 2218

Use of Anakinra in Hospitalized Patients with Acute Crystalline Arthritis

9:00AM-11:00AM

Abstract Number: 2241

What Can Variation in Clinical Practice Teach Us about Treatment Strategies for Patients with Gout?

9:00AM-11:00AM

Abstract Number: 2227

What Should be the Goals of Gout Therapy? a Patient Perspective